AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced positive preclinical data for ...
Preclinical AVB-406 data presented in three oral presentations demonstrate the power of the vMiXTM RNAi platform and support planned clinical initiation for Alzheimer’s disease by the end of 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results